The Effects of Bolus, Intermittent and Continuous Enteral Feeding on Blood Glucose and Feeding Intolerance in ICU Patients With Sepsis

Launched by UMRANIYE EDUCATION AND RESEARCH HOSPITAL · Apr 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how different methods of feeding can affect blood sugar levels and feeding tolerance in patients who are critically ill with sepsis. The researchers will compare three feeding techniques: bolus feeding (giving larger amounts of nutrition at once), intermittent feeding (giving nutrition at scheduled intervals), and continuous feeding (providing nutrition steadily over time). The goal is to find out which method works best for patients in the intensive care unit (ICU) who are on a ventilator and need specialized nutrition.

To participate in this study, eligible patients must be between 18 and 70 years old, have been in the ICU for more than three days, and have specific health conditions that allow for enteral feeding (nutrition provided through a tube). They should not have diabetes or certain other medical issues. If a patient joins the trial, they will receive one of the three feeding methods, and the team will monitor their blood sugar levels and tolerance to the feeding. It’s important to note that the trial is not yet recruiting participants, so it’s still in the planning phase.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Hospitalized in ICU for more than 3 days
• • Ages between 18-70 years
• • APACHI II is in the range of 8-25
• • BMI in the range of 18.5-30
• • Able to receive enteral nutrition from N/G
• • Intubated on ventilator support
• • No previous diagnosis of Diabetes Mellitus,
• • Those who have not had Gastro intestinal System surgery in the last 6 months
• • Patients not receiving inotropic support
• • not receiving hemodiafiltration
• • No history of allergy to the food used
• • Patients with a focus of infection and/or culture-positive patients diagnosed with sepsis according to Q SOFA (cultures were taken from all patients)
• Exclusion Criteria:
• • patient's death during the study
• • Taking more than 40 mg of IV steroids daily
• • Increased baseline APACHI II score
• • Development of the patient's need for inotropes
• • Elimination of inclusion criteria
• • negative culture